Fact based stock research
Takeda Pharmaceutical (TSE:4502)
JP3463000004
Takeda Pharmaceutical stock research in summary
Takeda Pharmaceutical shares are less expensive than other comparable stocks. They are good value and show above average growth, but are riskily financed. We recommend evaluating whether the future of the company Takeda Pharmaceutical is really as difficult as the low price of the stock suggests. If you believe that the future of the company is market-typical or even better, then this could be an argument for a share purchase.
Latest Obermatt Ranks
Value Rank | 85 | ![]() |
Growth Rank | 62 | ![]() |
Safety Rank | 6 | ![]() |
Combined Rank | 56 | ![]() |
Country | Japan |
Industry | Pharmaceuticals |
Index | Nikkei 225, TOPIX 100 |
Size class | XX-Large |
December 18, 2020. Stock data may be delayed. Login to get the most recent research.
Google: Takeda Pharmaceutical
Research History: Takeda Pharmaceutical
RESEARCH HISTORY | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
VALUE | ||||||||
VALUE | 89 |
![]() |
88 |
![]() |
85 |
![]() |
85 |
![]() |
GROWTH | ||||||||
GROWTH | 71 |
![]() |
67 |
![]() |
62 |
![]() |
62 |
![]() |
SAFETY | ||||||||
SAFETY | 38 |
![]() |
12 |
![]() |
6 |
![]() |
6 |
![]() |
COMBINED | ||||||||
COMBINED | 100 |
![]() |
57 |
![]() |
56 |
![]() |
56 |
![]() |
Value Metrics in Detail
VALUE METRICS | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
PRICE VS. REVENUES (P/S) | ||||||||
PRICE VS. REVENUES (P/S) | 66 |
![]() |
60 |
![]() |
65 |
![]() |
65 |
![]() |
PRICE VS. PROFITS (P/E) | ||||||||
PRICE VS. PROFITS (P/E) | 44 |
![]() |
29 |
![]() |
53 |
![]() |
53 |
![]() |
PRICE VS. CAPITAL (Market-to-Book) | ||||||||
PRICE VS. CAPITAL (Market-to-Book) | 80 |
![]() |
82 |
![]() |
78 |
![]() |
78 |
![]() |
DIVIDEND YIELD | ||||||||
DIVIDEND YIELD | 96 |
![]() |
98 |
![]() |
94 |
![]() |
94 |
![]() |
CONSOLIDATED RANK: VALUE | ||||||||
CONSOLIDATED RANK: VALUE | 89 |
![]() |
88 |
![]() |
85 |
![]() |
85 |
![]() |
Growth Metrics in Detail
GROWTH METRICS | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
REVENUE GROWTH | ||||||||
REVENUE GROWTH | 33 |
![]() |
88 |
![]() |
96 |
![]() |
96 |
![]() |
PROFIT GROWTH | ||||||||
PROFIT GROWTH | 71 |
![]() |
60 |
![]() |
26 |
![]() |
26 |
![]() |
STOCK RETURNS | ||||||||
STOCK RETURNS | 57 |
![]() |
32 |
![]() |
51 |
![]() |
51 |
![]() |
CONSOLIDATED RANK: GROWTH | ||||||||
CONSOLIDATED RANK: GROWTH | 71 |
![]() |
67 |
![]() |
62 |
![]() |
62 |
![]() |
Safety Metrics in Detail
SAFETY METRICS | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
LEVERAGE | ||||||||
LEVERAGE | 12 |
![]() |
8 |
![]() |
8 |
![]() |
8 |
![]() |
REFINANCING | ||||||||
REFINANCING | 28 |
![]() |
38 |
![]() |
47 |
![]() |
47 |
![]() |
LIQUIDITY | ||||||||
LIQUIDITY | 62 |
![]() |
31 |
![]() |
31 |
![]() |
31 |
![]() |
CONSOLIDATED RANK: SAFETY | ||||||||
CONSOLIDATED RANK: SAFETY | 38 |
![]() |
12 |
![]() |
6 |
![]() |
6 |
![]() |
Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Takeda Pharmaceutical from December 18, 2020.
We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.